Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study.
暂无分享,去创建一个
Wim Van Criekinge | David J Harrison | L. V. Neste | P. Delvenne | L. van Neste | D. Harrison | W. Van Criekinge | G. Stewart | P. Delrée | W. Criekinge | S. Mcneill | Philippe Delvenne | Agnès Delga | M. O’Donnell | James Clark | J. Bigley | Leander Van Neste | Paul Delrée | Grant D Stewart | Agnès Delga | S Alan McNeill | Marie O'Donnell | James Clark | Joseph Bigley | W. van Criekinge | D. Harrison | M. O'Donnell
[1] J. Patard,et al. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. , 2009, European urology.
[2] J. Epstein,et al. Optimal Use of a Panel of Methylation Markers with GSTP1 Hypermethylation in the Diagnosis of Prostate Adenocarcinoma , 2004, Clinical Cancer Research.
[3] Vijayalakshmi Ananthanarayanan,et al. Evidence for field cancerization of the prostate , 2009, The Prostate.
[4] F. Latif,et al. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. , 2005, Cancer research.
[5] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[6] R. Autorino,et al. Are extended biopsies really necessary to improve prostate cancer detection? , 2003, Prostate Cancer and Prostatic Diseases.
[7] J. Epstein,et al. Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy , 1999 .
[8] P. Carroll,et al. Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy. , 2001, The Journal of urology.
[9] R. Ablin. A retrospective and prospective overview of prostate-specific antigen , 1997, Journal of Cancer Research and Clinical Oncology.
[10] H Ballentine Carter,et al. Complications after prostate biopsy: data from SEER-Medicare. , 2011, The Journal of urology.
[11] B. Trock,et al. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high‐risk cohort of men with negative initial prostate biopsies , 2012, BJU international.
[12] J. Herman,et al. The Epigenetic promise for prostate cancer diagnosis , 2012, The Prostate.
[13] K. Chevli,et al. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients , 2013, The Prostate.
[14] Mesut Remzi,et al. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: Results of the prospective European prostate cancer detection study , 2001, The Prostate.
[15] J. Gillespie,et al. Gene promoter methylation in prostate tumor-associated stromal cells. , 2006, Journal of the National Cancer Institute.
[16] Jason Fine,et al. Sample size for positive and negative predictive value in diagnostic research using case-control designs. , 2008, Biostatistics.
[17] C C Schulman,et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? , 2001, The Journal of urology.
[18] M. Roobol,et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. , 2012, European urology.
[19] Robert E. Brown,et al. Field effect in cancer-an update. , 2009, Annals of clinical and laboratory science.
[20] D. Sidransky,et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. , 2001, Journal of the National Cancer Institute.
[21] J. Epstein,et al. Quantitative GSTP1 methylation levels correlate with Gleason grade and tumor volume in prostate needle biopsies. , 2004, The Journal of urology.
[22] M. Lucia,et al. Prostate Cancer Detected by Methylated Gene Markers in Histopathologically Cancer-Negative Tissues from Men with Subsequent Positive Biopsies , 2009, Cancer Epidemiology, Biomarkers & Prevention.
[23] J. Epstein,et al. A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection , 2012, BMC Urology.
[24] M. Hoque,et al. A Quantitative Promoter Methylation Profile of Prostate Cancer , 2004, Clinical Cancer Research.
[25] A. D. De Marzo,et al. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer , 2004, Journal of cellular biochemistry.
[26] D. Ornstein,et al. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. , 2000, The Journal of urology.
[27] A. Mazumder,et al. Quantitative, spatial resolution of the epigenetic field effect in prostate cancer , 2008, The Prostate.
[28] J. Epstein,et al. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. , 2003, The Journal of urology.
[29] A. Wellmann,et al. Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci , 2005, Clinical Cancer Research.